Harvard Bioscience (HBIO) Interest & Investment Income (2019 - 2026)

Harvard Bioscience (HBIO) has reported Interest & Investment Income for 8 consecutive years, with -$1.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 79.12% year-over-year to -$1.8 million in Q2 2026; TTM through Jun 2026 was -$6.8 million, a 72.42% decrease from a year earlier, with the FY2025 full-year figure at -$4.9 million, down 39.06% from the prior year.
• Interest & Investment Income was -$1.8 million for Q2 2026 at Harvard Bioscience, down from -$1.7 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at -$384000.0 in Q1 2022 and troughed at -$2.4 million in Q4 2025.
• A 5-year average of -$1.0 million and a median of -$916500.0 in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income plunged 153.65% in 2023 and climbed 22.9% in 2024, its largest moves.
• Over 5 years, Interest & Investment Income stood at -$900000.0 in 2022, then gained by 11.78% to -$794000.0 in 2023, then tumbled by 48.61% to -$1.2 million in 2024, then slumped by 99.83% to -$2.4 million in 2025, then climbed by 23.96% to -$1.8 million in 2026.
• The last three Interest & Investment Income figures came in at -$1.8 million (Q2 2026), -$1.7 million (Q1 2026), and -$2.4 million (Q4 2025), per Business Quant data.